Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Acurx Pharmaceuticals Stock Performance
NASDAQ:ACXP opened at $0.46 on Monday. The firm has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.29. Acurx Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $3.33.
Insider Transactions at Acurx Pharmaceuticals
In other news, CEO David P. Luci purchased 49,261 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the purchase, the chief executive officer now owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 29.60% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on ACXP
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- How to Build the Ultimate Everything ETF Portfolio
- Investing in Travel Stocks Benefits
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.